Status:

UNKNOWN

The Effectiveness of Albendazole Treatment Among Infected Toxocara Children

Lead Sponsor:

Pham Ngoc Thach University of Medicine

Collaborating Sponsors:

Department of Science and Technology, Ho Chi Minh City, Viet Nam

Conditions:

Toxocara Infection

Eligibility:

All Genders

3-15 years

Phase:

NA

Brief Summary

This study consists 2 phases. The first phase will conduct a cross-sectional study to determine the infection rate of Toxocariasis larvae, describe the clinical and paraclinical characteristics, ident...

Detailed Description

This study includes 2 phases below: Phase 1: Cross-sectional study Sample population: total 960 pupils aged 3-15 years old from public kindergartens, primary schools, and secondary schools in Ho Chi ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria for phase 1 study:
  • Pupils aged 3-15 years from Kindergarten to Secondary schools
  • Agreement from parents with writen informed consent
  • Inclusion criteria for intervention:
  • Children infected with toxocariasis may have symptoms and the ELISA test is positive for Toxocariasis larvae, with or without increased BCAT and IgE.
  • ELISA results according to the specified Kit and read according to optical densities (OD).
  • Cases of suspected heart, lung, liver, eye damage ... referred to Children's Hospital 2 for examination by specialty and not for intervention.
  • Exclusion Criteria:
  • Children aged 3-15 years without writen informed consent from parents and themselves.
  • Children infected with Toxocariasis larvae which are not common type.
  • Children infected with Toxocariasis are suffering from acute diseases or other chronic diseases: Cardiovascular, hepatitis, kidney, stomach, mental, or suspected tumor...
  • Children with a history of hypersensitivity to any ingredient in the treatment of Albendazole.
  • Infected children do not have enough follow-up process before and after 1, 6 months of treatment.

Exclusion

    Key Trial Info

    Start Date :

    May 1 2022

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    March 1 2024

    Estimated Enrollment :

    960 Patients enrolled

    Trial Details

    Trial ID

    NCT05208333

    Start Date

    May 1 2022

    End Date

    March 1 2024

    Last Update

    April 20 2022

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

    The Effectiveness of Albendazole Treatment Among Infected Toxocara Children | DecenTrialz